Abiopharma

New Form 8-K - COLLEGIUM PHARMACEUTICAL, INC Filed: 2025-08-07 AccNo: 0001558370-25-010647 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 10-Q - PRECISION BIOSCIENCES INC Filed: 2025-08-07 AccNo: 0001628280-25-038594 Size: 6 MB

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

New Form 10-Q - NORTECH SYSTEMS INC Filed: 2025-08-07 AccNo: 0001641172-25-022507 Size: 5 MB

New Form 10-Q - SAB Biotherapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104566 Size: 13 MB

New Form 10-Q - REGENXBIO Inc. Filed: 2025-08-07 AccNo: 0001193125-25-174953 Size: 15 MB

Silence Therapeutics - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Cybin - Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New Form 8-K - PRECISION BIOSCIENCES INC Filed: 2025-08-07 AccNo: 0001628280-25-038592 Size: 237 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Nuvation Bio Inc. Filed: 2025-08-07 AccNo: 0001193125-25-174954 Size: 319 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Nuvation Bio Inc. - Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates